Lin Shao-Lee, the Chief Executive Officer of Cue Biopharma, Inc., has sold 11,087 shares of the company's stock as part of a transaction to meet tax obligations. This sale, reported in a recent SEC filing, highlights the common practice among executives to manage their stock holdings in alignment with company policies.

These transactions were executed automatically to satisfy mandatory tax withholding obligations related to the vesting and settlement of restricted stock units. Shao-Lee did not have control over the timing, price, or number of shares sold, as noted in the filing.

Background

Cue Biopharma, Inc. operates in the pharmaceutical preparations sector, specifically focusing on innovative therapeutic solutions. The company is incorporated in Delaware and has its business address in Somerville, Massachusetts. Its recent filings include various forms, with the latest being a Form 4 submitted on October 14, 2026, detailing the stock transactions by its CEO.

What the Filing Says

The SEC filing indicates that on October 12, 2026, Shao-Lee sold 10,000 shares at a price of $27.50 each, followed by the sale of an additional 1,087 shares at $28.05. Following these transactions, Shao-Lee retains ownership of 694,908 shares.

Impact

This stock sale may affect Cue Biopharma's shareholders and potential investors, as executive transactions often draw attention to the company's financial health and governance practices. The pharmaceutical industry, particularly, is closely monitored for executive stock sales, which can signal confidence or concerns about company performance.

What's Next

The filing does not say what happens next.